Clinical outcomes following stereotactic body radiation therapy (SBRT) for Non-Spinal Bone Metastases: A Systematic Review and Meta-Analysis
Abstract
BACKGROUND
There is limited data available on clinical outcomes following stereotactic body radiation therapy (SBRT) for non-spinal bone metastases. We performed a systematic review and meta-analysis to characterize local control (LC), overall survival (OS), pain response rates, and toxicity following SBRT.
METHODS
Primary outcomes were 1-year LC, incidences of acute and late Grade 3-5 toxicities, and overall pain response rate at 3 months. The secondary outcome was 1-year OS. The Newcastle-Ottawa scale was employed for assessment of study bias, with a median score of 5⋆ for included studies (range: 4-8). Weighted random effects meta-analyses were conducted to estimate effect sizes.
RESULTS
We identified 528 patients with 597 non-spinal bone lesions across 9 studies, 1 prospective and 8 retrospective observational, treated with SBRT. The estimated 1-year LC rate was 94.6% (95% CI: 87.0-99.0%). The estimated 3-month combined partial and complete pain response rate following SBRT was 87.7% (95% CI: 55.1-100.0%). The estimated combined acute and late Grade 3-5 toxicity rate was 0.5% (95% CI: 0-5.0%) with an estimated pathologic fracture rate of 3.1% (95% CI: 0.2-9.1%). The estimated 1-year OS rate was 71.0% (95% CI: 51.7-87.0%).
CONCLUSIONS
SBRT resulted in excellent LC and palliation of symptoms with minimal related toxicity. Prospective investigations are warranted to further characterizes long-term outcomes with SBRT for patients with non-spinal bone metastases.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 528 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.